Psychiatric Quarterly

, Volume 66, Issue 1, pp 87–95 | Cite as

Bromocriptine and psychosis: A literature review

  • Alan Boyd


Bromocriptine is an ergot-derived dopamine agonist. Its current uses include the treatment of Parkinson's disease, postpartum ablaction, prolactionmas, acromegaly, and amenorrhea and galactorrhea secondary to neuroleptic use. It is often reported to produce psychiatric side effects such as confusion, hallucinations, and delusions. The literature is reviewed and supports a strong anecdotal relationship between bromocriptine use and psychosis.


Public Health Dopamine Acromegaly Bromocriptine Dopamine Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sibley DR, Monsma FJ, Jr: Molecular biology of dopamine receptors. Trends in Pharmacological Sciences 13(Feb):61–69, 1992.CrossRefPubMedGoogle Scholar
  2. 2.
    Wood DF, Johnston JM, Johnston DG: Dopamine, the dopamine receptor and putuitary tumors. Clinical Endocrinology 35:455–466, 1991.PubMedGoogle Scholar
  3. 3.
    Davis KL, Kahn RS, Ko, G, et al: Dopamine in schizophrenia: a review and reconceptualization. American Journal of Psychiatry 148(11):1474–1486, 1991.PubMedGoogle Scholar
  4. 4.
    Parkes D: Bromocriptine. New England Journal of Medicine 301:873–878, 1979.PubMedGoogle Scholar
  5. 5.
    Blackwell RE, Bradley EL, Kline LB, et al: Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: a multicenter study. Fertility and Sterility 39(6):744–748, 1983.PubMedGoogle Scholar
  6. 6.
    Robbins RJ, Kern PA, Thompson TL: Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. American Journal of Medicine 76(5):921–923, 1984.CrossRefPubMedGoogle Scholar
  7. 7.
    Brook NM, Cookson IB: Bromocriptine-induced mania? (Letter) British Medical Journal 1:790, 1978.Google Scholar
  8. 8.
    Vlissides DN, Gill D, Castelow J: Bromocriptine-induced mania? (Letter) British Medical Journal 1:510, 1978.Google Scholar
  9. 9.
    Lipper S: Psychosis in patient on bromocriptine and levodopa with carbidopa. Lancet 2(7985):571–572, 1976.CrossRefGoogle Scholar
  10. 10.
    Vogel HP, Schiffter R: Hypersexuality — a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatry 16:107–110, 1983.Google Scholar
  11. 11.
    Montastruc JL, Rascol O, Rascol A: A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. Journal of Neurology, Neurosurgery, and Psychiatry 52:773–775, 1989.Google Scholar
  12. 12.
    Ostergaard K, Dupont, E: Clozapine treatment of drug-induced psychotic symptoms of late stages of Parkinson's disease. Acta Neurologica Scandinavica 78:349–350, 1988.PubMedGoogle Scholar
  13. 13.
    Scholz E, Dichgans J: Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. European Archives of Psychiatry and Neurological Sciences 235:60–64, 1985.CrossRefPubMedGoogle Scholar
  14. 14.
    Serby M, Angrist B, Lieberman A: Mental disturbances during bromocriptine and lergotrile treatment of Parkinson's disease. American Journal of Psychiatry 135:1227–1229, 1978.PubMedGoogle Scholar
  15. 15.
    Cummings, JL: Behavioral complications of drug treatment of Parkinson's disease. Journal of the American Geriatrics Society 39:708–716, 1991.PubMedGoogle Scholar
  16. 16.
    Calne DB, Williams AC, Neophytides A, et al: Long-term treatment of Parkinsonism with bromocriptine. Lancet 1(8067):735–738, 1978.CrossRefPubMedGoogle Scholar
  17. 17.
    Burton K, Larsen TA, Robinson RG, et al: Parkinson's disease: a comparison of mesulergine and bromocriptine. Neurology 35:1205–1208, 1985.PubMedGoogle Scholar
  18. 18.
    Friedman JH, Max J, Swift, R: Idiopathic Parkinson's disease in a chronic schizophrenic patient: long-term treatment with clozapine and l-dopa. Clinical Neuropharmacology 10(5):470–475, 1987.PubMedGoogle Scholar
  19. 19.
    Iffy L, Lindenthal J, Szodi Z, et al: Puerperal psychosis following ablaction with bromocriptine. Medicine and Law 8(2):171–174, 1989.PubMedGoogle Scholar
  20. 20.
    Canterbury RJ, Haskins B, Kahn N, et al: Postpartum psychosis induced by bromocriptine. Southern Medical Journal 80(11):1463–1464, 1987.PubMedGoogle Scholar
  21. 21.
    Kemperman CJF, Zwanniken GJ: Psychiatric side effects of bromocriptine therapy for postpartum galactorrhoea. Journal of the Royal Society of Medicine 80:387–388, 1987.PubMedGoogle Scholar
  22. 22.
    Lake CR, Reid A, Martin C, et al: Cyclothymic disorder and bromocriptine: predisposing factors for postpartum mania? Canadian Journal of Psychiatry 32:693–694, 1987.Google Scholar
  23. 23.
    Steinbeck K, Turtle JR: Treatment of acromegaly with bromocriptine. Australian and New Zealand Journal of Medicine 9:217–224, 1979.PubMedGoogle Scholar
  24. 24.
    LeFeuvre CM, Isaacs AJ, Frank OS: Bromocriptine-induced psychosis in acromegaly. British Medical Journal 285:1315, 1982.Google Scholar
  25. 25.
    Vance ML, Evans WS, Thorner MO: Bromocriptine. Annals of Internal Medicine 100:78–91, 1984.PubMedGoogle Scholar
  26. 26.
    Cabeza GA, Flores LF, Inigues IE, et al: Acute psychosis secondary to bromocriptine treatment in a patient with a prolactinoma. Revista de Investigacion Clinica 36(2):147–149, 1984.PubMedGoogle Scholar
  27. 27.
    Einarson TR, Turchet, EN: Psychotic reaction to low-dose bromocriptine. Clinical Pharmacy 2(May–June):273–274, 1983.PubMedGoogle Scholar
  28. 28.
    Turner TH, Cookson JC, Wass JAH, et al: Psychotic reactions during treatment of pituitary tumors with dopamine agonists. British Medical Journal 289:1101–1103, 1984.PubMedGoogle Scholar
  29. 29.
    Shukla S, Turner WJ, Newman G: Bromocriptine-related psychosis and treatment. Biological Psychiatry 20:326–328, 1985.CrossRefPubMedGoogle Scholar
  30. 30.
    Taneli B, Ozaskinli S, Kirli S, et al: Bromocriptine-induced schizophrenic syndrome. American Journal of Psychiatry 143(7):935, 1986.Google Scholar
  31. 31.
    Johnson JM: Treated mania exacerbated by bromocriptine. American Journal of Psychiatry 138:980–982, 1981.PubMedGoogle Scholar
  32. 32.
    Pearson KC: Mental disorders from low dose bromocriptine (Letter). New England Journal of Medicine 305:173, 1978.Google Scholar
  33. 33.
    Procter AW, Littlewood R, Fry AH: Bromocriptine-induced psychosis in acromegaly. British Medical Journal 286:50, 1983.PubMedGoogle Scholar
  34. 34.
    Frye PE, Pariser SF, Kim MH, et al: Bromocriptine associated with symptom exacerbation during neuroleptic treatment of schizoaffective schizophrenia. Journal of Clinical Psychiatry 43(6):252–253, 1982.PubMedGoogle Scholar
  35. 35.
    Dorevitch A, Aronzon R, Stark M: Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstetricia et Gynecologica Scandinavica 70:375–376, 1991.PubMedGoogle Scholar
  36. 36.
    Turner WJ: Importance of treatment follow-up. Biological Psychiatry 28:551–554, 1990.CrossRefPubMedGoogle Scholar
  37. 37.
    Einarson TR, Turchet EN: Follow-up on bromocriptine-induced psychosis. Clinical Pharmacy 2(Nov–Dec):512, 1983.Google Scholar
  38. 38.
    Beaumont PJV, Gelder MG, Friesen HG, et al: The effects of phenothiazines on endocrine function: I Patients with inappropriate lactation and amenorrhea. British Journal of Psychiatry 124:413–419, 1974.PubMedGoogle Scholar
  39. 39.
    Beaumont P, Bruwer J, Pimstone B, et al: Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhea. British Journal of Psychiatry 126:285–288, 1975.PubMedGoogle Scholar
  40. 40.
    Perovich RM, Lieberman JA, Fleischhacker WW, et al: The behavioral toxicity of bromocriptine in patients with psychiatric illness. Journal of Clinical Psychopharmacology 9(6):417–422, 1989.PubMedGoogle Scholar

Copyright information

© Human Sciences Press, Inc. 1995

Authors and Affiliations

  • Alan Boyd
    • 1
  1. 1.Tulane Medical Center, Department of Psychiatry and NeurologyTulane UniversityNew Orleans

Personalised recommendations